The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 17 April 2026•Updated 17 April 2026•

1 min read

UK's Intertek Rejects $11 Billion Takeover Proposal from EQT

FDA and Novo Nordisk logos above a laboratory scene with computer monitors, chemical structures, medicine bottles, and pills.

Key Facts

1UK testing specialist Intertek rejected a non-binding takeover approach from Swedish private equity firm EQT.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Updated the story to include the $11 billion valuation of the bid and Intertek's characterization of the approach as unsolicited.

British testing and inspection specialist Intertek has rejected a non-binding, unsolicited takeover proposal from Swedish private equity firm EQT, valued at approximately $11 billion. The FTSE 100-listed company characterized the approach as unsolicited, signaling its commitment to a standalone strategic roadmap. The rejection occurred as Intertek evaluates a potential demerger of its business units, a move that helped drive shares higher in London trading. Intertek's board believes the $11 billion valuation significantly undervalues the company's long-term growth prospects and intrinsic worth. Market analysts are now watching for a potential sweetened bid from EQT or the emergence of rival suitors. This development underscores the persistent interest of global private equity in high-quality UK industrial service providers.